FLERIE — Flerie AB Share Price
0.000.00%
Last trade - 00:00- SEK251.43m
- -SEK16.35m
- SEK97.51m
- 13
- 25
- 62
- 23
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.13 | ||
| Price to Tang. Book | 1.13 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.45 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -27.57% | ||
| Return on Equity | -21.38% | ||
| Operating Margin | -60.39% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 0.09 | 0.04 | n/a | n/a | 97.5 | n/a | 168 | 277.02% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Flerie AB, formerly InDex Pharmaceuticals Holding AB, is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is an active long-term global biotech and pharmaceutical investor that managing a portfolio of companies in Europe, Israel, and the US. Flerie invests in companies across the entire value chain, providing exposure to opportunities across three segments: Product Development, Commercial Growth, and Limited Partnerships. The Product Development segment consists of early-stage biotech and pharma companies in product development. The Commercial Growth segment consists of companies that are already selling products or services and showcasing proof-of-concept with high growth and some that have already reached profitability. The Limited Partnerships segment provides benefits for the other two segments, including co-investment opportunities, and derisks Flerie’s investment portfolio.
Directors
- Wenche Rolfsen NEC (69)
- Peter Zerhouni CEO (44)
- Johan Gileus CFO (56)
- Pernilla Sandwall COO (57)
- Thomas Knittel OTH (54)
- Marlene Forsell IND (45)
- Uli Hacksell IND (71)
- Lennart Hansson IND (63)
- Stig Loekke Pedersen IND (60)
- Yilmaz Mahshid IND (42)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- June 27th, 2016
- Public Since
- October 11th, 2016
- No. of Employees
- 7
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 532,687,650
- Address
- Skeppsbron 16, STOCKHOLM, 111 30
- Web
- https://www.flerie.com/
- Phone
- +46 812203850
- Contact
- Johan Gileus
- Auditors
- PricewaterhouseCoopers AB
Upcoming Events for FLERIE
Q3 2024 InDex Pharmaceuticals Holding AB Earnings Release
Similar to FLERIE
Biogaia AB
OMX Nordic Exchange Stockholm
BoneSupport Holding AB
OMX Nordic Exchange Stockholm
Calliditas Therapeutics AB
OMX Nordic Exchange Stockholm
Camurus AB
OMX Nordic Exchange Stockholm
Cinclus Pharma Holding publ AB
OMX Nordic Exchange Stockholm
FAQ
What is the Flerie AB share price?
As of Today at 20:41 UTC, shares in Flerie AB are trading at SEK0.50. This share price information is delayed by 15 minutes.
How has the Flerie AB share price performed this year?
Shares in Flerie AB last closed at SEK0.50 and the price had moved by -8.61% over the past 365 days. In terms of relative price strength the Flerie AB share price has underperformed the FTSE Global All Cap Index by -19.63% over the past year.
What are the analyst and broker recommendations for Flerie AB?
The overall consensus recommendation for Flerie AB is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Flerie AB dividend yield?
Flerie AB does not currently pay a dividend.
Does Flerie AB pay a dividend?
Flerie AB does not currently pay a dividend.
When does Flerie AB next pay dividends?
Flerie AB does not currently pay a dividend.
How do I buy Flerie AB shares?
To buy shares in Flerie AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Flerie AB?
As of the previous close price of SEK0.50, shares in Flerie AB had a market capitalisation of SEK265.81m.
Where are Flerie AB shares listed?
Here are the trading details for Flerie AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: FLERIE
What kind of share is Flerie AB?
Based on an overall assessment of its quality, value and momentum Flerie AB is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Flerie AB share price forecast for 2024?
The analyst consensus target price for shares in Flerie AB is SEK0.27. That is 45.89% below the last closing price of SEK0.50.
Analysts covering Flerie AB currently have a consensus Earnings Per Share (EPS) forecast of -SEK0.49 for the next financial year.
What is the trend in the Flerie AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Flerie AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +90.35%.
As of the last closing price of SEK0.50, shares in Flerie AB were trading +11.45% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Flerie AB PE Ratio?
The Flerie AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK0.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Flerie AB?
Flerie AB's management team is headed by:
- Wenche Rolfsen - NEC
- Peter Zerhouni - CEO
- Johan Gileus - CFO
- Pernilla Sandwall - COO
- Thomas Knittel - OTH
- Marlene Forsell - IND
- Uli Hacksell - IND
- Lennart Hansson - IND
- Stig Loekke Pedersen - IND
- Yilmaz Mahshid - IND